B2 anti-EIIIB CAR T cells

B2 anti-EIIIB CAR T cells are an experimental, nanobody-based chimeric antigen receptor (CAR) T-cell therapy designed to target the tumor microenvironment (TME) rather than tumor cells directly. Developed by researchers at Boston Children's Hospital and MIT, these cells utilize a camelid-derived single-domain antibody fragment (nanobody) called VHH NJB2 to recognize EIIIB, an alternatively spliced domain of fibronectin. EIIIB is highly expressed in the extracellular matrix (ECM) and neovasculature of various solid tumors but is largely absent in healthy adult tissues. By targeting the supportive infrastructure of the tumor, the B2 CAR T cells aim to disrupt nutrient supply and physical barriers, potentially enhancing immune infiltration and drug accessibility. Preclinical studies in immunocompetent mouse models of melanoma and colon cancer have demonstrated their ability to slow tumor growth and improve survival by inducing vascular and stromal damage.

Other names

anti-EIIIB CAR T cellsVHH NJB2-based CAR T cellsanti-FN-EIIIB CAR T cells